FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114847255> ?p ?o ?g. }

• W2114847255 endingPage "294" @default.
• W2114847255 startingPage "287" @default.
• W2114847255 abstract "Background In some patients with critical limb ischemia (CLI) the possibility of revascularizing treatment does not exist. In this case therapeutic angiogenesis (TA) using autologous endothelial progenitor cell (EPC) transplantation could be an alternative. The objective of our study was to evaluate the safety and efficacy of TA using EPC. Methods Twenty-eight patients with CLI who were not candidates for surgical or endovascular revascularization were included in a prospective study. To mobilize EPCs from the bone marrow, granulocyte colony-stimulating growth factor was injected subcutaneously at doses of 5 μg/kg/day for 5 days. Apheresis was performed, obtaining 50 mL of blood with a high rate of EPCs (CD34+ and CD133+ cells were counted). EPCs were implanted in the ischemic limb by intramuscular injections. Primary end points were the safety and feasibility of the procedure and limb salvage rate for amputation at 12 months. Other variables studied were improvement in rest pain, healing of ulcers, ankle-brachial pressure index (ABI), and digital plethysmography. All procedures were done pretreatment and every 3 months for a year on average. Postransplantation arteriography was done in selected cases. Results No adverse effects were observed. Mean follow-up was 14 months. Before treatment, mean basal ABI was 0.35±0.2 and at 18 months postimplantation, 0.72±0.51 (p=0.009). There was a mean decrease of five points in pain scale: basal 8.7±1, after TA 3.8±2.9 (p=0.01). Seven patients required major amputation. Kaplan-Meier analysis revealed a limb salvage rate of 74.4% after 1 year. Conclusion Implantation of EPCs in CLI is a safe alternative, improves tissue perfusion, and obtains high amputation-free rates. Nevertheless, this is a small cohort and results should be tested with long randomized trials. In some patients with critical limb ischemia (CLI) the possibility of revascularizing treatment does not exist. In this case therapeutic angiogenesis (TA) using autologous endothelial progenitor cell (EPC) transplantation could be an alternative. The objective of our study was to evaluate the safety and efficacy of TA using EPC. Twenty-eight patients with CLI who were not candidates for surgical or endovascular revascularization were included in a prospective study. To mobilize EPCs from the bone marrow, granulocyte colony-stimulating growth factor was injected subcutaneously at doses of 5 μg/kg/day for 5 days. Apheresis was performed, obtaining 50 mL of blood with a high rate of EPCs (CD34+ and CD133+ cells were counted). EPCs were implanted in the ischemic limb by intramuscular injections. Primary end points were the safety and feasibility of the procedure and limb salvage rate for amputation at 12 months. Other variables studied were improvement in rest pain, healing of ulcers, ankle-brachial pressure index (ABI), and digital plethysmography. All procedures were done pretreatment and every 3 months for a year on average. Postransplantation arteriography was done in selected cases. No adverse effects were observed. Mean follow-up was 14 months. Before treatment, mean basal ABI was 0.35±0.2 and at 18 months postimplantation, 0.72±0.51 (p=0.009). There was a mean decrease of five points in pain scale: basal 8.7±1, after TA 3.8±2.9 (p=0.01). Seven patients required major amputation. Kaplan-Meier analysis revealed a limb salvage rate of 74.4% after 1 year. Implantation of EPCs in CLI is a safe alternative, improves tissue perfusion, and obtains high amputation-free rates. Nevertheless, this is a small cohort and results should be tested with long randomized trials." @default.
• W2114847255 created "2016-06-24" @default.
• W2114847255 creator A5010077050 @default.
• W2114847255 creator A5034531877 @default.
• W2114847255 creator A5036156015 @default.
• W2114847255 creator A5078180788 @default.
• W2114847255 creator A5080510511 @default.
• W2114847255 creator A5081168775 @default.
• W2114847255 date "2010-02-01" @default.
• W2114847255 modified "2023-10-01" @default.
• W2114847255 title "Safety and Efficacy of Therapeutic Angiogenesis as a Novel Treatment in Patients with Critical Limb Ischemia" @default.
• W2114847255 cites W147423764 @default.
• W2114847255 cites W1978139448 @default.
• W2114847255 cites W1981285537 @default.
• W2114847255 cites W1997797780 @default.
• W2114847255 cites W1999579644 @default.
• W2114847255 cites W2002495385 @default.
• W2114847255 cites W2022248346 @default.
• W2114847255 cites W2024950877 @default.
• W2114847255 cites W2028639104 @default.
• W2114847255 cites W2060548737 @default.
• W2114847255 cites W2065886428 @default.
• W2114847255 cites W2066877588 @default.
• W2114847255 cites W2070646800 @default.
• W2114847255 cites W2071107976 @default.
• W2114847255 cites W2076202270 @default.
• W2114847255 cites W2078462957 @default.
• W2114847255 cites W2079678426 @default.
• W2114847255 cites W2081830616 @default.
• W2114847255 cites W2085778192 @default.
• W2114847255 cites W2087665223 @default.
• W2114847255 cites W2103227975 @default.
• W2114847255 cites W2112267683 @default.
• W2114847255 cites W2115932678 @default.
• W2114847255 cites W2122661129 @default.
• W2114847255 cites W2124403472 @default.
• W2114847255 cites W2126611738 @default.
• W2114847255 cites W2127872440 @default.
• W2114847255 cites W2130761693 @default.
• W2114847255 cites W2133762215 @default.
• W2114847255 cites W2136409449 @default.
• W2114847255 cites W2143499157 @default.
• W2114847255 cites W2148711016 @default.
• W2114847255 cites W2155090369 @default.
• W2114847255 cites W2167233400 @default.
• W2114847255 cites W4243820570 @default.
• W2114847255 cites W65095426 @default.
• W2114847255 doi "https://doi.org/10.1016/j.avsg.2009.10.012" @default.
• W2114847255 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20142004" @default.
• W2114847255 hasPublicationYear "2010" @default.
• W2114847255 type Work @default.
• W2114847255 sameAs 2114847255 @default.
• W2114847255 citedByCount "108" @default.
• W2114847255 countsByYear W21148472552012 @default.
• W2114847255 countsByYear W21148472552013 @default.
• W2114847255 countsByYear W21148472552014 @default.
• W2114847255 countsByYear W21148472552015 @default.
• W2114847255 countsByYear W21148472552016 @default.
• W2114847255 countsByYear W21148472552017 @default.
• W2114847255 countsByYear W21148472552018 @default.
• W2114847255 countsByYear W21148472552019 @default.
• W2114847255 countsByYear W21148472552020 @default.
• W2114847255 countsByYear W21148472552021 @default.
• W2114847255 countsByYear W21148472552022 @default.
• W2114847255 countsByYear W21148472552023 @default.
• W2114847255 crossrefType "journal-article" @default.
• W2114847255 hasAuthorship W2114847255A5010077050 @default.
• W2114847255 hasAuthorship W2114847255A5034531877 @default.
• W2114847255 hasAuthorship W2114847255A5036156015 @default.
• W2114847255 hasAuthorship W2114847255A5078180788 @default.
• W2114847255 hasAuthorship W2114847255A5080510511 @default.
• W2114847255 hasAuthorship W2114847255A5081168775 @default.
• W2114847255 hasConcept C126322002 @default.
• W2114847255 hasConcept C141071460 @default.
• W2114847255 hasConcept C2776204877 @default.
• W2114847255 hasConcept C2778271429 @default.
• W2114847255 hasConcept C2778486273 @default.
• W2114847255 hasConcept C2779464278 @default.
• W2114847255 hasConcept C2780394083 @default.
• W2114847255 hasConcept C2781099653 @default.
• W2114847255 hasConcept C2781188250 @default.
• W2114847255 hasConcept C500558357 @default.
• W2114847255 hasConcept C71924100 @default.
• W2114847255 hasConceptScore W2114847255C126322002 @default.
• W2114847255 hasConceptScore W2114847255C141071460 @default.
• W2114847255 hasConceptScore W2114847255C2776204877 @default.
• W2114847255 hasConceptScore W2114847255C2778271429 @default.
• W2114847255 hasConceptScore W2114847255C2778486273 @default.
• W2114847255 hasConceptScore W2114847255C2779464278 @default.
• W2114847255 hasConceptScore W2114847255C2780394083 @default.
• W2114847255 hasConceptScore W2114847255C2781099653 @default.
• W2114847255 hasConceptScore W2114847255C2781188250 @default.
• W2114847255 hasConceptScore W2114847255C500558357 @default.
• W2114847255 hasConceptScore W2114847255C71924100 @default.
• W2114847255 hasIssue "2" @default.
• W2114847255 hasLocation W21148472551 @default.
• W2114847255 hasLocation W21148472552 @default.
• W2114847255 hasOpenAccess W2114847255 @default.

• next